SCHEMBL6285038

SCHEMBL6285038

COc1ccc(-c2cc3c([nH]2)CCCC3)cc1NC(=S)Nc1cc(Cl)cc(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.49
ALDH1A1 P00352 6/20 0.49
MEN1 O00255 5/20 0.49
LMNA P02545 4/20 0.49
MAPT P10636 3/20 0.49
HPGD P15428 1/20 0.49
GAA P10253 4/20 0.43
KDM4E B2RXH2 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6285043 0.79 LMNA (0.38) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL6496744 0.78 KMT2A (0.51) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL6286002 0.77 KMT2A (0.50) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL6286353 0.77 ALDH1A1 (0.50) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL6504811 0.77 KMT2A (0.49) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL6288146 0.76 ALDH1A1 (0.48) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL6279218 0.76 RIPK1 (0.55) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL6285013 0.75 ALDH1A1 (0.47) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL6288171 0.75 KMT2A (0.49) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL6286947 0.75 KMT2A (0.52) KMT2AALDH1A1MEN1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US claimed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP claimed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO claimed
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US disclosed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US disclosed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP disclosed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014759-A1 6,5-Fused bicyclic heterocycles ALOX15, ALOX5, ALOX15B KMT2A 4200/4885ALDH1A1 522/4885MEN1 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.